Partner Success: Nimbus Apollo
Pharmaron is proud to be a part of our partners’ successes, and the Gilead acquisition of Nimbus Apollo, Inc. is certainly no exception.
The Nimbus Apollo program includes the lead compound ‘976, where Pharmaron’s chemistry, biology, DMPK and process chemistry teams, under the direction of Nimbus scientists, played an instrumental role in the discovery of this candidate. We continue to be a major partner for Nimbus in their research efforts after the ACC deal with Gilead.
Written with permission by Nimbus.
Learn more about our small molecule services
